



GENOMICS | GENETICS | R&D | DIAGNOSTIC TESTS

Genomic Vision: press release regarding changes in the Company's governance

Bagneux (France) - GENOMIC VISION (FR0011799907 – GV – the “Company”), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced changes in its governance structure following the Company's ordinary general meeting held on July 11, 2022 (the “**General Meeting**”) and the Company's Supervisory Board meeting held on July 21, 2022 (the “**Supervisory Board meeting**”).

The shareholders' General Meeting decided to revoke Mrs. Elisabeth Ourliac, Mrs. Tammou Abikhzer and Mr. Stéphane Verdood's mandates as members of the Company's Supervisory Board, it being specified that these revocations ended Mrs. Elisabeth Ourliac and Mr. Stéphane Verdood's tenure as Chair and Vice-Chair of the Supervisory Board. Furthermore, the shareholders' General Meeting also decided to revoke Mrs. Dominique Remy-Renou's mandate as a member of the Executive Board.

Following these decisions, during the General Meeting, the Company's shareholders approved the appointment of Mrs. Florence Allouche, Mr. Mohammad Afshar and Mr. Eric Edery as independent members of the Supervisory Board for a six-year term as provided for in the Company's articles of association.

Following the General Meeting, the reconstituted Supervisory Board met on July 21, 2022 and unanimously decided to:

- appoint Mr. Aaron Bensimon as Chair of the Executive Board for the duration of his mandate as a member of said Board, it being specified that this appointment ends his mandate as Chief Executive Officer of Genomic Vision;
- appoint Mrs. Florence Allouche as Chair of the Supervisory Board for the duration of her mandate as a member of said Board;
- appoint Mr. Eric Edery as Vice-Chair of the Supervisory Board for the duration of his mandate as a member of said Board; and
- set the number of Executive Board members at three and appoint Mrs. Emilie Chataignier and Mr. Lionel Seltz as members of the Executive Board for the remaining duration of their mandates as members of said Board.

Mrs. Florence Allouche, Chairwoman of Genomic Vision's Supervisory Board, said: *"It gives me great pleasure to be the new Chair of Genomic Vision's Supervisory Board. Eric, Mohammad and I will combine our complementary fields of expertise and experience and use them to advance Genomic Vision's ambitious strategy."*

Mr. Aaron Bensimon, Chairman of Genomic Vision's Executive Board, commented: *"The appointment of a new Supervisory Board with highly qualified members who are international experts in our industry is a strong step forward for the Company and our ambitions. I would like to thank Florence, Eric and Mohammad for their commitment and their enthusiasm."*

Moreover, I am very pleased to welcome Emilie and Lionel to their new positions, both bringing a fresh and independent perspective to Genomic Vision. I am convinced that Emilie's international experience in finance and in investment banking, as well as her expertise in delivering sustainable solutions, will be invaluable as we grow our business. Lionel is an experienced CFO in healthtech, bringing significant knowledge of financing, development and corporate structuring. Their strong experience and their desire to be a part of an ambitious project will be valuable assets for the Company's development.

I would also like to thank Mrs. Dominique Remy-Renou, Mrs. Elisabeth Ourliac, Mrs. Tammou Abikhzer and Mr. Stéphane Verdood for their contribution to the work undertaken by Genomic Vision's Executive and Supervisory Boards in recent years."

Readers are also reminded that the Company has chosen to refer to the Corporate Government Code published by MiddleNext (the "**MiddleNext Code**") to organize its governance. At the Supervisory Board meeting, the Supervisory Board's members examined the situation of that Board's members with respect to the independence criteria defined by the MiddleNext Code and determined that all the members of the Supervisory Board are deemed to be independent members within the meaning of the MiddleNext Code. Furthermore, given the new composition of the Supervisory Board, at the Supervisory Board meeting the members designated the following people as members of the Audit Committee:

- Mrs. Florence Allouche, as Chair of that committee; and
- Mr. Eric Edery.

Mrs. Florence Allouche, Chairwoman of Genomic Vision's Supervisory Board, stated in this respect that *"Mr. Eric Edery possesses the financial, accounting and auditing skills required to meet the recommendations of the Middlednext Code that the Company follows"*.

At the Supervisory Board meeting, the members of the Supervisory Board also designated the following people as members of the Appointments and Compensation Committee:

- Mrs. Florence Allouche, as Chair of that committee, and
- Mr. Mohammad Afshar.

Lastly, regarding these changes in the Company's governance, Mr. Aaron Bensimon, Chairman of Genomic Vision's Executive Board, commented: *"The aim of these changes in Genomic Vision's governance is to further strengthen the international aspect and diversity of experience and expertise. Very high-value-added R&D investments and strong sales momentum are the cornerstones of the Company's new ambition."*

The minutes of the shareholders' General Meeting of July 11, 2022 are available in the Investors / [General Assembly](#) section of the Company's website.

* * *

Biographies:

Members of the Executive Board:

Mr. Aaron Bensimon, Chair of the Executive Board:

Doctor of Molecular Biology, he founded Genomic Vision in 2004, before being appointed CEO of the Company in May 2006. He is also the Company's Scientific Director.

Over the course of his tenure, Dr Bensimon forged several partnerships with key players in the pharma and biotech sector including with Quest Diagnostics, Editas Medicine, Sanofi Aventis and AstraZeneca, amongst others, and successfully led the Company's IPO on Euronext in 2014.

Dr. Aaron Bensimon jointly discovered the DNA "molecular combing" process. With unique expertise in this technology and its applications in molecular diagnostics, he has made a significant contribution to the development of this discipline and has published numerous articles in prestigious scientific journals (Science, Nature, Cell, etc.)

He is the author of more than 20 patent filings concerning molecular combing.

Before founding Genomic Vision, he spent 15 years as a researcher at the Pasteur Institute in Paris where, from 1994, he headed the Genome Stability Unit. It was during his research in collaboration with the *Ecole Normale Supérieure Paris'* statistical physics laboratory that he discovered the DNA molecular combing process.

In 1995, he received the Jacques Monod award from the *Fondation de France*, which recognizes young researchers who have made significant breakthroughs at the beginning of their careers.

From 1992 to 1993, he worked in Prof. Jean-Pierre Changeux's laboratory (Pasteur Institute, Paris). His research focused on studying the myogenin gene's involvement in muscle denervation. This project was financed by the prestigious "Human Frontier Science Program" grant obtained after earning his doctorate at the Weizmann Institute in Israel.

Aaron Bensimon has also followed the prestigious HEC business school's "Challenges+" management training and regularly speaks at scientific conferences.

Mrs. Emilie Chataignier, member of the Executive Board:

Initially trained in Mathematics Applied to Social Sciences at Paris Dauphine University, Émilie Chataignier spent 18 years working in investment banking, from France with international partners.

As an analyst, trader and intermediary on the equity markets, she facilitated transactions and discussions between French-speaking institutional investors and listed American companies. She is also trained in mediation and commercial conflict management and in interest-based negotiation, and since 2021 has been practicing as a judicial and conventional mediator with both large and small companies.

Emilie Chataignier uses mediation, communication tools and her network of investors, business leaders and experts, but also her experience in risk analysis and value creation, to assist business leaders with their governance, in particular during transitions. Convinced that power struggles are counterproductive in the long run, she ensures that the interests of all parties (the company, all the company's members, regulators, all industrial and financial partners) are respected. She encourages creativity in the search for responsible and sustainable solutions, whether in prevention before partnerships are entered into or in the amicable settlement of commercial and social disputes.

Mr. Lionel Seltz, member of the Executive Board and Chief Financial Officer:

Lionel Seltz is responsible for the oversight of the Company's global finances, its corporate development and the implementation of its strategy.

Lionel Seltz joined Genomic Vision in August 2022 from Intrasense, a Euronext-Growth-listed MedTech where he was Group CFO. In that role, Lionel steered finance and funding operations as well as the Company's structuring. Prior to that, Lionel Seltz co-founded a technological startup in France after spending 6 years in Asia (Singapore and Tokyo) working for IQVIA. While at IQVIA (formerly IMS Health and Quintiles), a leading global supplier of advanced analytics, technological solutions and epidemiological research services to the life sciences industry, Lionel Seltz was APAC CFO for the Technological division and then headed the integration and restructuring of newly acquired businesses.

Earlier in his career, he notably served as M&A Director and International Development Manager for Cegedim, a listed company specializing in HealthTech.

Lionel Seltz obtained his master's degree in international business from Strasbourg University in France and followed several executive courses in corporate finance, strategy and digital marketing at the prestigious HEC business school in Paris.

Members of the Supervisory Board:**Mrs. Florence Allouche, Chair of the Supervisory Board:**

PharmD - Paris University, MBA - HEC Paris, Board Director certified - IFA/Sciences Po Paris. Biologist at AP-HP (Greater Paris Hospitals), Florence has held several positions within the diagnostics industry.

She created and spent 16 years running the AP-HP Tech Transfer Office. 1,000 patent families filed, 300 licensing agreements signed, €25 million in annual revenue, 75 startups created. Expert & mentor for the main Paris incubators, she represented the French technology transfer at international level (AUTM, ASTP).

In 2016, Florence Allouche cofounded and was CEO of SparingVision, a genomic medicines company, transforming 20 years of state-of-the-art ophthalmic research at the Paris Vision Institute into sight-saving treatments for retinitis pigmentosa, moving beyond single gene correction therapies to gene-independent treatments. SparingVision raised €60 million in series A and recently €75 million in series B and obtained several grants.

Florence Allouche is a Professor at Paris Cité University's Faculty of Pharmacy, specialized in pharmaceutical innovation and entrepreneurship. She is founder and President of Myrpharm Advisors, a consulting firm helping translational academic research through startup creation, tech transfer, business development, innovation management, funding, strategy, growth and mentoring.

(Member of the French National Academy of Pharmacy, Member of the EIT Health Venture Center of Excellence Scientific Advisory Board, Prev. Member of the supervisory board of the Big Investment Plan oversight committee under the authority of the French Prime Minister (SGI), First Prize Biotech in the CATAPULT 2019 European Startups Competition, Finalist in the Prix Galien International, New York (US) - Med'Startup, 2019, Mercure Entrepreneurs award - HEC Paris 2019, Women's Trajectory award - HEC Paris 2018, Named "Woman of the Year 2017" by French financial magazine "La Tribune".)

Mr. Eric Ederly, Vice-Chair of the Supervisory Board:

Eric J.Ederly is a financial advisor and Venture Capital fund partner.

Graduating in Finance from the Sorbonne, Eric spent 10 years working at Morgan Stanley Dean Witter in Paris on a Sovereign Debt desk and in an Equity Sales department prior to joining the Private Wealth division in Zurich. Since 2016, he has been advising Tech and Biotech companies across Europe. He is on the Advisory Board of WebInfluence Group, an Adtech company.

Mr. Mohammad Afshar, member of the Supervisory Board:

Mohammad Afshar is the founder and CEO of Ariana Pharma, a drug development company based in Paris (France) and Boston (USA) specializing in Artificial Intelligence (AI). Ariana Pharma specializes in precision medicine clinical trials, transforming multi-omic data into innovative clinical development plans and regulatory approvals.

Prior to joining Ariana Pharma, Mohammad Afshar was founder and Director of Drug Design at RiboTargets, Cambridge, UK. He set up and managed the platform that discovered and successfully patented several novel therapeutic molecules. Before joining RiboTargets, he held several academic positions, notably in York University's Chemistry Department in the UK and the CNRS' CRBM research institute in France. He holds a Medical Degree (DCEM), a master's in computer science (DEA), a PhD in structural biochemistry and a PhD HDR (enabling him to lead research projects) from Montpellier University's Faculty of Medicine in France. Since 2014, he has been on the Seventure Partners VC fund's investment advisory board.

* * *

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

CONTACTS**Genomic Vision**

Aaron Bensimon
Président du Directoire
Tél. : +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication

Relations Presse
Bruno Arabian
Tél. : +33 1 42 68 29 70
barabian@ulyссе-communication.com

**Consilium Strategic
Communications**

International Investor Relations
& Strategic Communications
Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com

NewCap

Domestic Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu



Membre des indices **CAC® Mid & Small** et **CAC® All-Tradable**

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.